Login / Signup

Response to: 'Increased risk for severe COVID-19 in patients with inflammatory rheumatic diseases treated with rituximab' by Schulze-Koops et al.

Sara MontiCarlomaurizio Montecucco
Published in: Annals of the rheumatic diseases (2020)
Keyphrases
  • coronavirus disease
  • sars cov
  • diffuse large b cell lymphoma
  • early onset
  • oxidative stress
  • hodgkin lymphoma
  • chronic lymphocytic leukemia
  • respiratory syndrome coronavirus
  • newly diagnosed